Table 3.
Sex difference in uEV NCC and pNCC measured by immunoblotting
| Proteins | Female |
Males (N = 4, 22.2%) | P (female vs. male) | P (premenopausal female vs. male) | P (postmenopausal female vs. male) | |||
|---|---|---|---|---|---|---|---|---|
| All females (N = 14, 77.8%) | Premenopausal (n = 8, 57.1%) | Postmenopausal (n = 6, 42.9%) | P (premenopausal vs. postmenopausal) | |||||
| NCC | ||||||||
| Placebo | 1.12 [0.2, 5.2] | 1.3 [0.7, 5.2] | 0.8 [0.2, 1.8] | 0.094 | 2.0 [1.1, 2.7] | 0.051 | 0.33 | 0.03 |
| Active | 0.9 [0.1, 1.7] | 1.2 [0.6, 1.7] | 0.5 [0.1, 1.4] | 0.035 | 1.4 [0.8, 1.7] | 0.11 | 0.72 | 0.03 |
| P (active vs. placebo) | 0.03 | 0.32 | 0.018 | 0.02 | ||||
| pNCC | ||||||||
| Placebo | 1.0 [0.4, 6.7] | 1.3 [0.4, 6.7] | 0.7 [0.4, 2.5] | 0.43 | 2.5 [0.8, 3.3] | 0.19 | 0.37 | 0.13 |
| Active | 1.1 [0.2, 2.0] | 1.2 [0.5, 1.4] | 0.7 [0.2, 2.0] | 0.35 | 1.6 [0.9, 2.3] | 0.12 | 0.25 | 0.12 |
| P (active vs. placebo) | 0.12 | 0.37 | 0.077 | 0.11 | ||||
NCC, sodium chloride cotransporter; pNCC, phosphorylated sodium chloride cotransporter; uEV, urinary extracellular vesicle.